Fadi Alghzawi

Comparative Cardiorenal Efficacy and Safety of SGLT2 Inhibitors and Finerenone in Chronic Kidney Disease With Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis

ABSTRACT Aims No randomized trial has compared SGLT2 inhibitors with finerenone in chronic kidney disease (CKD) with Type 2 diabetes. We estimated their comparative cardiorenal efficacy and safety. Materials and Methods MEDLINE, Embase, CENTRAL and trial registries were searched...